Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2HER3 Solid Tumors - Benzinga

HILSDelisted Stock  USD 0.39  0.01  2.50%   
Slightly above 62% of Hillstream Biopharma's investor base is looking to short. The analysis of current outlook of investing in Hillstream Biopharma suggests that many traders are alarmed regarding Hillstream Biopharma's prospects. Hillstream Biopharma's investing sentiment can be driven by a variety of factors including economic data, Hillstream Biopharma's earnings reports, geopolitical events, and overall market trends.
  
Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2HER3 Solid Tumors Benzinga

Read at news.google.com
Google News at Macroaxis
  

Hillstream Biopharma Fundamental Analysis

We analyze Hillstream Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hillstream Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hillstream Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Shares Owned By Insiders

Shares Owned By Insiders Comparative Analysis

Hillstream Biopharma is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Hillstream Biopharma Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Hillstream Biopharma stock to make a market-neutral strategy. Peer analysis of Hillstream Biopharma could also be used in its relative valuation, which is a method of valuing Hillstream Biopharma by comparing valuation metrics with similar companies.

Peers

Hillstream Biopharma Related Equities

ZVSAZyVersa Therapeutics   24.58   
0%
100.0%
VRAXVirax Biolabs   3.42   
0%
13.0%
PALIPalisade Bio   4.98   
20.0%
0%
KPRXKiora Pharmaceuticals   5.63   
22.0%
0%
QNRXQuoin Pharmaceuticals   6.06   
24.0%
0%
IMMXImmix Biopharma   6.67   
27.0%
0%
CDIOCardio Diagnostics   8.22   
33.0%
0%
REVBRevelation Biosciences   8.62   
35.0%
0%
UNCYUnicycive Therapeutics   10.81   
43.0%
0%
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Other Consideration for investing in Hillstream Stock

If you are still planning to invest in Hillstream Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hillstream Biopharma's history and understand the potential risks before investing.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated